On July 13, 2026, the FDA approved Leqembi IQLIK (lecanemab-irmb) as a subcutaneous starting dose for early Alzheimer's disease, meaning patients can now begin treatment entirely at home instead of starting with intravenous infusions. This guide lays out what the approval covers and what to ask an Alzheimer's specialist before switching to the at-home option. Leqembi IQLIK is an autoinjector version of lecanemab, an antibody drug that targets amyloid plaques in the brain. Until this expansion, the device was cleared only for patients who had already completed 18 months of IV treatment; the new approval lets appropriate patients skip IV infusions from day one, according to Eisai and Biogen's July 2026 announcement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Explore the official data from FDA — Use this primary source to review the underlying data.
- Read the official guidance from Biospace — Use this primary source to verify the official guidance.
Table of Contents
- What changed with this approval, and who qualifies?
- How is the at-home starting dose actually given?
- What safety monitoring is required before and during treatment?
- When did it become available, and what does it cost?
- Frequently Asked Questions
What changed with this approval, and who qualifies?
Before July 2026, Leqembi IQLIK was approved only for once-weekly 360 mg maintenance dosing, and only after a patient had finished 18 months of biweekly IV lecanemab in a clinic or infusion center, as reported by FiercePharma. The new approval adds a starting-dose option, so a newly diagnosed patient can begin the entire course of treatment with the autoinjector rather than ever starting on IV. The approval applies to adults with early Alzheimer's disease, defined as mild cognitive impairment or mild dementia caused by Alzheimer's and confirmed through amyloid-pathology testing (such as a PET scan or spinal fluid test).
Patients can also move between IV and subcutaneous administration during the course of treatment, per Epocrates' August 2026 overview. A specialist can confirm two things before this is a realistic option: whether amyloid pathology has been documented for a specific patient, and whether their stage of disease still falls within "early" Alzheimer's as defined in the label. Ask directly: "Does my loved one's diagnosis and test history meet the criteria for starting on the autoinjector instead of IV?".
How is the at-home starting dose actually given?
The approved initiation regimen is 500 mg once a week, delivered as two consecutive 250 mg injections, each taking about 15 seconds, according to the Eisai/Biogen release covered by BioSpace. That is a meaningful shift from the prior IV initiation schedule, which required biweekly infusions at a clinic.
Because the two injections are given back-to-back each week, a specialist should walk through exactly who administers them — a caregiver, a visiting nurse, or the patient — and where the training for that happens. Questions worth asking:.
- Who will train me or my family member to give the injections correctly?
- What happens if a weekly dose is missed or given late?
- Is there a visiting-nurse or in-home support option if self-injection isn't realistic?
What safety monitoring is required before and during treatment?
Leqembi carries an FDA boxed warning — the agency's strongest warning label — because amyloid-directed antibodies like lecanemab can cause ARIA (amyloid-related imaging abnormalities), including brain hemorrhages larger than 1 cm that can be serious, life-threatening, or fatal. This risk applies the same way whether the drug is given by IV or by injection, per the FDA-approved prescribing label. The label requires ApoE ε4 genotype testing — a blood or genetic test — before starting treatment, because people with two copies of the ε4 gene variant (homozygotes) face a higher ARIA risk than those with one copy or none.
Prescribers are required to discuss this risk with patients and families before the first dose, according to the same FDA label. A baseline brain MRI is also required before the first injection, with periodic follow-up MRIs during treatment to watch for ARIA — a requirement that carries over unchanged from IV initiation to the at-home starting dose, as confirmed by Epocrates. Worth asking a specialist directly:.
- Has the ApoE genotype test already been done, and what did it show?
- When is the baseline MRI scheduled, and how often will follow-up scans happen once home injections start?
- What symptoms (headache, confusion, vision changes, seizures) should prompt an immediate call rather than waiting for the next scan?
When did it become available, and what does it cost?
Eisai and Biogen made Leqembi IQLIK commercially available for starting treatment on August 24, 2026, distributed through specialty pharmacy rather than dispensed at an infusion clinic, according to Managed Healthcare Executive. That distribution channel matters practically: a specialist's office needs to coordinate with a specialty pharmacy rather than simply administering the drug on-site.
The wholesale acquisition cost is $385 per autoinjector, which means the two-injection weekly starting dose lists at $770 a week before insurance. Eisai's patient assistance program provides the drug at no cost to eligible uninsured patients, per the same Managed Healthcare Executive report. Questions to bring to a specialist or their billing staff:.
- What will insurance actually cover for the at-home starting dose, and is prior authorization required?
- Does my family qualify for the manufacturer's patient assistance program?
- Which specialty pharmacy handles delivery, and how is the medication stored once it arrives at home?
Frequently Asked Questions
Can someone switch from the at-home injections back to IV lecanemab later?
Yes — patients can move between IV and subcutaneous administration during the course of treatment, according to Epocrates.
Does starting with the autoinjector skip IV infusions entirely?
It can — the July 2026 approval lets eligible patients begin the full course of treatment on the subcutaneous starting dose instead of biweekly IV infusions, per Eisai and Biogen's announcement.
Is the ApoE genotype test optional?
No — the FDA label states it should be performed before starting treatment, since ε4 homozygotes carry a higher ARIA risk, per the prescribing label.
You Might Also Like
- Why the AAIC 2026 Soccer Study Does Not Prove Dementia: How Adults With Memory Concerns Can Avoid Overreading the Headline
- Healthy Diets in the 2026 WHO Dementia Guideline: Access and Adherence Barriers for People With Mild Cognitive Impairment
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Result Interpretation Questions for Adults With New Memory Symptoms
